Table 1.
Prospective clinical studies with results available.
| Drugs | ICI Target |
Schemes | N | ORR (%) | Median PFS (Months) | Median OS (Months) | Reference |
|---|---|---|---|---|---|---|---|
| Monotherapy (all for pretreated advanced EC) | |||||||
| Atezolizumab | PD-L1 | 15 mg/kg or 1200 mg IV Q3W | 15 | 13.3 | 1.4 (4.2 for IC2/3 cases) | 9.6 | [43] |
| Nivolumab | PD-1 | 240 mg IV Q2W | 23 | 23 | 3.4 | NA | [44] |
| Avelumab | PD-L1 | 10 mg/kg IV Q2W | 15 dMMR 16 pMMR |
26.7 6.25 |
4.4 6.25 |
Not reached 6.6 |
[45] |
| Durvalumab | PD-L1 | 1500 mg IV Q4W | 36 dMMR 35 pMMR |
47 3 |
5.5 1.8 |
Not reached 11.5 |
[46] |
| Pembrolizumab | PD-1 | 10 mg/kg IV Q2W | 24 PDL1+ | 13 | 1.8 | Not reached | [47] |
| 200 mg IV Q3W | 107 unselected 49 MSI-H |
11.2 57.1 |
NA 26.0 |
NA Not reached |
[48,49] | ||
| Dostarlimab | PD-1 | 500 mg IV Q3W for 4 doses then 1000 mg IV Q6W |
103 dMMR 142 pMMR |
44.7 13.4 |
NA NA |
NA NA |
[50] |
| Combinations | |||||||
| Pembrolizumab + lenvatinib | PD-1 | 200 mg IV Q3W + 20 mg orally once per day Single-arm ph2 in pretreated EC |
94 pMMR 11 dMMR |
24 W-ORR 36.2% 63.6% |
7.4 for the whole set | 16.7 for the whole set | [51] |
| 200 mg IV Q3W + 20 mg orally once per day Randomized ph3 vs. chemo in pretreated EC |
697 pMMR 130 dMMR |
NA | 6.6 vs. 3.8 for pMMR HR = 0.60 (95CI 0.50–0.72) |
17.4 vs. 12.0 for pMMR HR = 0.68 (95CI 0.56–0.84) |
[52] | ||
| Nivolumab ± cabozantinib | PD-1 | 240 mg IV Q2W ± 40 mg orally once per day Ph 2 randomized study |
36 nivo + cabo 18 nivo |
25.0 16.7 |
5.3 1.9 p = 0.07 (significant) |
NA | [53] |
| Avelumab + talazoparib | PD-L1 | 1200 mg IV Q3W +1 mg orally once per day Single-arm ph2 for pretreated EC |
35 pMMR | 8.6 | 6m-PFS = 25.8% | NA | [54] |
Abbreviations: ICI, immune-checkpoint inhibitor; ORR, overall response rate; PFS, progression-free survival; OS, overall survival; EC, endometrial cancer; IC, tumor-infiltrating immune cell; dMMR, MMR deficient; pMMR, MMR proficient; MSI-H, microsatellite instability-high; NA, not available.